Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acadia Pharmaceuticals Q4 net loss declines
For the year ended December 31, 2008, Acadia reported a net loss of $64.2 million, or $1.73 per share, compared to a net loss of $56.4 million, or
For the year ended December 31, 2008, Acadia reported a net loss of $64.2 million, or $1.73 per share, compared to a net loss of $56.4 million, or
Endo Pharmaceuticals, a specialty pharmaceutical company, has licensed the exclusive rights to develop and market the investigational drug axomadol in the US and Canada from the German pharmaceutical
The net loss in the fourth quarter of 2008 as compared to the net income in the fourth quarter of 2007 was due to an increase in operating
The company reported a net loss of $6.65 million, or $0.21 per share, for the year ended December 31, 2008, compared to a net loss of $6.22 million,
Net loss for the year ended December 31, 2008 was $47 million, or $0.56 per diluted share, compared to a net loss of $99.3 million, or $1.39 per
Medline Industries, a privately held manufacturer and distributor of medical supplies, has signed a three-year agreement with Premier to provide advanced wound care products to the Catholic Healthcare
Astellas Pharma and XenoPort, a biopharmaceutical company, have reported preliminary top-line results from a Phase II clinical trial of ASP8825/XP13512 for the treatment of symptoms in moderate-to-severe primary
Vertex Pharmaceuticals, a biotechnology company, has announced that it will add two polymerase inhibitors to its hepatitis C virus drug development portfolio through a definitive agreement to acquire
A concurrent $6 million financing included Commonwealth Capital, Oxford Bioscience, Flagship Ventures, Life Sciences Partners, FLIR Systems, Healthcare Ventures, New Science Ventures and HLM Venture Partners. Jay Teich,
According to Trinity, TRI-stat is designed to measure HbA1c, also known as glycated hemoglobin, a measure of a patient’s average blood sugar control over the last two to